Councilmark Asset Management LLC Acquires New Holdings in McKesson Corporation $MCK

Councilmark Asset Management LLC bought a new stake in McKesson Corporation (NYSE:MCK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,307 shares of the company’s stock, valued at approximately $7,032,000. McKesson comprises approximately 3.7% of Councilmark Asset Management LLC’s portfolio, making the stock its 7th biggest holding.

Several other large investors also recently added to or reduced their stakes in MCK. BlackRock Inc. bought a new position in shares of McKesson during the 2nd quarter valued at $8,156,743,000. State Street Corp increased its position in McKesson by 0.5% during the fourth quarter. State Street Corp now owns 5,780,179 shares of the company’s stock worth $4,746,118,000 after buying an additional 29,660 shares during the last quarter. Geode Capital Management LLC increased its position in McKesson by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 2,857,344 shares of the company’s stock worth $2,333,520,000 after buying an additional 25,082 shares during the last quarter. Franklin Resources Inc. raised its holdings in McKesson by 5.4% during the fourth quarter. Franklin Resources Inc. now owns 2,825,954 shares of the company’s stock valued at $2,318,102,000 after buying an additional 144,633 shares in the last quarter. Finally, Norges Bank bought a new position in McKesson during the fourth quarter valued at about $1,651,137,000. 85.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MCK has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their target price on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Evercore reissued an “outperform” rating on shares of McKesson in a research report on Thursday, August 6th. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a research report on Friday, May 8th. Finally, Barclays lifted their price objective on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.44.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion. The transaction would add clinical research, consulting and biopharma commercialization capabilities to McKesson’s oncology-focused business, broadening its exposure to higher-growth healthcare services. Reuters article about McKesson’s Precision Medicine acquisition
• Positive Sentiment: McKesson raised its fiscal 2027 earnings outlook as oncology demand, GLP-1 volumes and specialty pharmaceutical distribution accelerate. The higher guidance reinforces expectations for double-digit earnings growth and supports investor confidence in the company’s growth strategy. McKesson FY2027 guidance article
• Positive Sentiment: Short interest fell 33% to about 2.42 million shares as of August 14, representing roughly 2.1% of shares outstanding and 2.2 days of average trading volume. The decline suggests reduced bearish positioning and may provide additional support for the stock.
• Neutral Sentiment: Healthcare stocks broadly advanced late Tuesday, giving McKesson a favorable sector backdrop. However, sector-wide gains do not necessarily reflect company-specific fundamentals. Healthcare sector update
• Negative Sentiment: Analysts caution that McKesson’s premium valuation leaves less room for execution setbacks. Drug-pricing pressure, potential policy changes and cash-flow demands associated with expansion and acquisitions remain risks to the investment thesis. McKesson valuation analysis

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total value of $6,715,898.28. Following the completion of the transaction, the chief executive officer directly owned 5,919 shares in the company, valued at approximately $4,697,081.64. This represents a 58.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 23,111 shares of company stock valued at $18,011,274. Company insiders own 0.06% of the company’s stock.

McKesson Price Performance

NYSE:MCK opened at $904.31 on Wednesday. McKesson Corporation has a one year low of $673.38 and a one year high of $999.00. The company has a fifty day moving average price of $825.22 and a 200 day moving average price of $844.60. The stock has a market cap of $105.43 billion, a P/E ratio of 24.20, a PEG ratio of 1.72 and a beta of 0.30.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. The company had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the business posted $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, equities research analysts anticipate that McKesson Corporation will post 44.65 EPS for the current year.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 1st. This is a boost from McKesson’s previous quarterly dividend of $0.82. McKesson’s payout ratio is 8.78%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.